Today's Rundown UPDATED: Amgen's KRAS drug shows promise in 2 additional cancers: colorectal and appendiceal Meet GEn1E, the biotech bringing p38alpha kinase drugs to inflammatory diseases Gilead looks to Galapagos deal to double research capacity Wellington raises €210M fund to back European biotechs Frontier Medicines bolsters leadership team with new CSO, tech hires Verastem signs on Stuglik as CEO Featured Story | | | Tuesday, July 30, 2019 Two months after posting the first clinical data for a KRAS inhibitor, Amgen is at it again. The Big Pharma reported in its second-quarter earnings presentation that AMG 510 shrank tumors in patients with colorectal and appendiceal cancers. |
|
|
Top Stories Wednesday, July 31, 2019 GEn1E Lifesciences' first target is acute respiratory distress syndrome, a disease in which fluid leaks into the lungs that has no FDA-approved treatment. Wednesday, July 31, 2019 Daniel O’Day has framed Gilead’s $5.1 billion megadeal with Galapagos as a way to double its research capacity. The Gilead CEO told investors his company will benefit from having two drug discovery operations feeding into its clinical-phase pipeline. Wednesday, July 31, 2019 Wellington Partners has raised a €210 million ($234 million) life science fund to back biotechs in German-speaking parts of Europe and beyond. The fund sets Wellington up to invest in 15 to 20 drug development and medical device companies. Wednesday, July 31, 2019 A month out from launch, Frontier Medicines is building out its team. The company is working to find new binding pockets on previously “undruggable” proteins, and to get there, it’s picked up a trio of biopharma veterans. Tuesday, July 30, 2019 Verastem Oncology has a new leader: Brian Stuglik, the Eli Lilly veteran who sat on Verastem’s board of directors. Stuglik’s appointment comes a month after Robert Forrester stepped down from the CEO post. Resources Sponsored by: Veeva This white paper details how leveraging new reporting capabilities, live UAT feedback sessions, and an agile design approach to study builds will save them time and money. Sponsored by: BBK Worldwide The Study Voices survey challenges the myth that physicians won’t refer patients to clinical trials, and it identifies opportunities to engage physicians as partners in the enrollment process. Sponsored by: Cambrex The highest number of NCEs approved by the FDA…the fastest growing small molecule clinical pipeline reported in 20 years…these are exciting times for our industry. Sponsored by: Reprints Desk, Inc. Cut your research time in half - with an easy-to-use app for scientists that combines full-featured reference management with integrated search and on-demand document delivery. Sponsored by: Almac Group Innovative Just in Time Manufacturing solution enables sponsors full late stage customisation of clinical trial materials Sponsored by: PwC How are employer activism strategies beginning to replace the cost-sharing of the past, and improve the health of the workforce? Sponsored by: United Cargo and SAVSU Technologies The combination of SAVSU technology with United Airlines’ global network has made it easier than ever to bring cell and gene therapies to destinations beyond major markets. Sponsored by: XiltriX North America Find out in this article how your pharmaceutical organization can leverage IoT technologies and informatics integration to innovate and improve overall operational efficiencies. Sponsored by: Patheon, by Thermo Fisher Scientific When a biologics company prepares to launch a new product, it must forecast the manufacturing capacity it will need. Learn more here. Sponsored by: Veradigm Patient demand for more information on their care is driving new e-prescribing regulations, and technology is evolving to help providers meet them. This report provides an overview of key areas where such regulation has emerged, and what it could mean for providers and healthcare IT companies. Sponsored by: Patheon, by Thermo Fisher Scientific Anticipate challenges in formulation early. Sponsored by: Catalent Download the case study to learn about the clinical supply management tools that helped a small sized pharma company during phase III of a multi-arm oncology study. Sponsored by: Catalent Watch a short video on demand led supply model. It is designed to meet the needs of patients, clinical sites, clinical team and sponsors and results in shorter lead time, less waste, less stock out risk and no booklet labels. Sponsored by: Catalent Download the eBook to explore a proactive approach for clinical supply management. Latin America Healthcare Compliance Certificate Program September 23-26, 2019 4th FierceBiotech Drug Development Forum October 28-29, 2019 | Boston, MA Drug Development Boot Camp® 2019 November 20-21, 2019 | Boston, MA | Register NOW and start Pre-Boot Camp Preparation! | 